As Trump backs psychedelics research, FDA weighs safety and access standards
By Nancy LapidThe U.S. FDA heard calls for clear safety and access standards for psychedelic therapies at a public meeting, the latest step in the Trump administration's push to speed development of treatments such as ibogaine and psilocybin.Presently, almost all psychedelic drugs in the United Sta…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.